| A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (NCT07638566) | argenx | 2026-09-01 |
| A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) (NCT07746089) | argenx | 2026-09-01 |
| A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy (NCT07610564) | argenx | 2026-07-27 |
| A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults (NCT07583641) | argenx | 2026-07-13 |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis (NCT07673627) | argenx | 2026-07-10 |
| A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants (NCT07673601) | argenx | 2026-06-12 |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. (NCT07596849) | argenx | 2026-06-10 |
| A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants (NCT07612020) | argenx | 2026-03-16 |
| A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy (NCT07595653) | argenx | 2026-02-25 |
| A Study to Assess the Safety of ARGX-124 in Healthy Volunteers (NCT07377396) | argenx | 2026-01-26 |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy (NCT07287982) | argenx | 2025-12-19 |
| ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis (NCT07294170) | argenx | 2025-12-19 |
| ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod (NCT07284420) | argenx | 2025-12-19 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) (NCT07194850) | argenx | 2025-10-20 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP (NCT07091630) | argenx | 2025-09-16 |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP (NCT06920004) | argenx | 2025-08-22 |
| Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study (NCT07264426) | argenx | 2025-08-11 |
| A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) (NCT06909214) | argenx | 2025-04-17 |
| A Study to Assess the Safety of ARGX-213 in Healthy Volunteers (NCT06968338) | argenx | 2025-04-11 |
| A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome (NCT06684847) | argenx | 2025-01-15 |
| A Study to Assess the Safety of ARGX-109 in Healthy Volunteers (NCT06799416) | argenx | 2025-01-14 |
| A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy (NCT06742190) | argenx | 2024-12-18 |
| A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC (NCT06637072) | argenx | 2024-12-10 |
| A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis (NCT06655155) | argenx | 2024-11-11 |
| A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (NCT06441682) | argenx | 2024-10-23 |
| A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia (NCT06544499) | argenx | 2024-10-18 |
| A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) (NCT06436742) | argenx | 2024-09-24 |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis (NCT06558279) | argenx | 2024-09-18 |
| A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) (NCT06503731) | argenx | 2024-08-30 |
| A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis (NCT06284954) | argenx | 2024-08-20 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (NCT06298552) | argenx | 2024-04-16 |
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease (NCT06307613) | argenx | 2024-03-27 |
| ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (NCT05907096) | argenx | 2024-02-17 |
| A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4 (NCT06078553) | argenx | 2024-02-13 |
| A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding. (NCT06299748) | argenx | 2023-11-30 |
| A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy (NCT05988073) | argenx | 2023-11-29 |
| Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome (NCT06203457) | argenx | 2023-11-29 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (NCT05979441) | argenx | 2023-09-12 |
| A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod (NCT05927415) | argenx | 2023-07-17 |
| Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS (NCT05918978) | argenx | 2023-06-20 |
| A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) (NCT05817669) | argenx | 2023-04-04 |
| A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (NCT05681481) | argenx | 2023-03-22 |
| A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults (NCT05817435) | argenx | 2023-03-13 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) (NCT05810948) | argenx | 2023-02-21 |
| A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants (NCT05670704) | argenx | 2023-02-21 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) (NCT05810961) | argenx | 2023-02-20 |
| A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy (NCT05405361) | argenx | 2023-01-18 |
| A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (NCT05523167) | argenx | 2022-10-12 |
| Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS (NCT05633407) | argenx | 2022-09-23 |
| A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (NCT05267600) | argenx | 2022-06-09 |
| A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy (NCT05225675) | argenx | 2022-03-31 |
| An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (NCT04980495) | argenx | 2021-12-16 |
| Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV (NCT05163834) | argenx | 2021-11-17 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (NCT04812925) | argenx | 2021-11-17 |
| Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis (NCT04833894) | argenx | 2021-10-26 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (NCT04598477) | argenx | 2021-07-15 |
| Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (NCT04735432) | argenx | 2021-02-05 |
| A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (NCT04687072) | argenx | 2020-12-16 |
| A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (NCT04598451) | argenx | 2020-12-01 |
| SAD and MAD Study With IV and SC Doses of ARGX-117 (NCT04532125) | argenx | 2020-08-03 |
| A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) (NCT04274452) | argenx | 2020-06-29 |
| A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (NCT04225156) | argenx | 2020-06-02 |
| A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (NCT04281472) | argenx | 2020-04-15 |
| A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (NCT04188379) | argenx | 2019-12-16 |
| Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects (NCT04073589) | argenx | 2019-07-17 |
| A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (NCT03770403) | argenx | 2019-03-01 |
| An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (NCT03669588) | argenx | 2018-08-22 |
| A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus (NCT03334058) | argenx | 2017-10-18 |
| A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects (NCT03334084) | argenx | 2017-10-11 |